MAKO Surgical Corp. (Nasdaq:MAKO) today announced it ranked No. 1
on Deloitte's Technology Fast 500™, ranking of the 500 fastest
growing technology, media, telecommunications, life sciences and
clean technology companies in North America.
MAKO's president and chief executive officer, Maurice R. Ferré,
M.D., attributes MAKO's success to the exceptionally talented team
members who have been instrumental in developing, commercializing
and supporting its innovative robotic arm technology and implant
systems.
"Our commitment to provide solutions for the treatment of
osteoarthritis that focus on restoring patients' quality of
life has been and will continue to be the driving force in our
growth," said Maurice R. Ferré. "We are honored to be recognized
among Deloitte's Technology Fast 500TM."
"MAKO, like all 2011 Technology Fast 500™ companies, has
excelled in fostering innovation and channeling it into spectacular
growth -- against the backdrop of one of the most challenging
economies in history," said Eric Openshaw, vice chairman and U.S.
technology, media and telecommunications leader, Deloitte LLP.
"Deloitte recognizes MAKO for its remarkable accomplishment."
"We are pleased to honor MAKO as a 2011 Technology Fast 500
company," said Mark Jensen, managing partner, technology and
venture capital services, Deloitte & Touche LLP. "As one of the
fastest growing tech companies in North America, MAKO has
demonstrated excellence in technological innovation,
entrepreneurship and rapid growth."
About Deloitte's 2011 Technology Fast 500™
Technology Fast 500, which was conducted by Deloitte &
Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the
fastest growing technology, media, telecommunications, life
sciences and clean technology companies – both public and private -
in North America. Technology Fast 500 award winners are selected
based on percentage fiscal year revenue growth from 2006 to 2010.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company's operating revenues. Companies must have base-year
operating revenues of at least $50,000 USD or CD, and current-year
operating revenues of at least $5 million USD or CD. Additionally,
companies must be in business for a minimum of five years, and be
headquartered within North America.
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets
both its RIO® Robotic-Arm Interactive Orthopedic system and its
proprietary RESTORIS® implants for orthopedic knee and hip
procedures called MAKOplasty®. The RIO is a surgeon-interactive
tactile surgical platform that incorporates a robotic arm and
patient-specific visualization technology, which enables precise,
consistently reproducible bone resection for the accurate insertion
and alignment of MAKO's RESTORIS implants. The MAKOplasty solution
is comprised of technologies enabled by an intellectual property
portfolio including more than 300 U.S. and foreign, owned and
licensed, patents and patent applications. Additional information
can be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing" or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability
to control or predict. Such factors, among others, may have a
material adverse effect on MAKO's business, financial condition and
results of operations and may include the potentially significant
impact of a continued economic downturn or delayed economic
recovery on the ability of MAKO's customers to secure adequate
funding, including access to credit, for the purchase of MAKO's
products or cause MAKO's customers to delay a purchasing decision,
changes in competitive conditions and prices in MAKO's markets,
unanticipated issues relating to intended product launches,
decreases in sales of MAKO's principal product lines, increases in
expenditures related to increased or changing governmental
regulation or taxation of MAKO's business, unanticipated issues in
complying with regulatory requirements related to MAKO's current
products or securing regulatory clearance or approvals for new
products or upgrades or changes to MAKO's current products, the
impact of the recently enacted United States healthcare reform
legislation on hospital spending, reimbursement, and the taxing of
medical device companies, loss of key management and other
personnel or inability to attract such management and other
personnel and unanticipated intellectual property expenditures
required to develop, market, and defend MAKO's products. These and
other risks are described in greater detail under Item 1A, "Risk
Factors," in MAKO's periodic filings with the Securities and
Exchange Commission, including MAKO's annual report on Form 10-K
for the year ended December 31, 2010 filed on March 10, 2011. Given
these uncertainties, undue reliance should not be placed on these
forward-looking statements. MAKO does not undertake any obligation
to release any revisions to these forward-looking statements
publicly to reflect events or circumstances after the date of this
press release or to reflect the occurrence of unanticipated
events.
"MAKOplasty®," "RESTORIS®," and "RIO®," as well as the "MAKO"
logo, whether standing alone or in connection with the words "MAKO
Surgical Corp." are trademarks of MAKO Surgical Corp.
CONTACT: MEDIA CONTACTS:
Yvette Cuello
MAKO Surgical Corp.
954-609-5085
mcuello@makosurgical.com
Cynthia Kalb
MAKO Surgical Corp.
954-218-9133
ckalb@makosurgical.com
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024